资讯

生物谷3 年
肺动脉高压(PAH)新药！美国FDA批准强生Uptravi(赛乐西帕)静脉制剂 ...
在PAH患者中，由于疾病的进展性，应避免中断治疗。此次批准的新制剂，允许暂时无法口服治疗的PAH患者进行不间断的治疗。 Uptravi是一种选择性 ...
生物谷4 年
肺动脉高压(PAH)新药！强生Uptravi静脉制剂在美国申请上市：用于暂时 ...
在PAH患者中，由于疾病的进展性，应避免中断治疗。 Uptravi是一种选择性前列环素IP受体激动剂。2015年，FDA批准口服Uptravi治疗PAH，以延缓疾病进展并 ...
The American Journal of Managed Care3 年
Macitentan Associated With Right Ventricular Function, Structure Improvement in PAH
RV failure accounts for most deaths among patients with PAH; a defining feature of the ... information relating to RV function and structure,” and “is regarded as the most accurate ...
Pulmonary Hypertension News9 天
Targeting gut microbes may be strategy for PAH treatment: Study
Transplanting gut microbes from healthy rats into a rat model of PAH led to a reduction in disease severity, suggesting a ...
The American Journal of Managed Care5 个月
High Uric Acid Appears to Have Causal Role in PAH
Hyperuricemia may causally contribute to PAH, positioning uric acid as a potential therapeutic target for treatment and prevention. Mendelian randomization analysis suggests a genetic-level causal ...
BioWorld2 年
ANPA-0073 and ANPA-0137, G protein-biased APJ agonists with efficacy in models of IPF and PAH
Researchers from Structure Therapeutics Inc. recently presented details on the discovery and preclinical evaluation of two new apelin receptor (APJ, APLNR) agonists – ANPA-0073 and ANPA-0137 – being ...